scispace - formally typeset
P

Pablo Gastaminza

Researcher at Spanish National Research Council

Publications -  53
Citations -  5568

Pablo Gastaminza is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Hepatitis C virus & Viral replication. The author has an hindex of 22, co-authored 47 publications receiving 5191 citations. Previous affiliations of Pablo Gastaminza include University of Barcelona & Carlos III Health Institute.

Papers
More filters
Journal ArticleDOI

Analysis of the interaction of influenza virus polymerase complex with human cell factors.

TL;DR: The interactions recognised in this proteomic approach suggest that the influenza polymerase might be involved in steps of the infection cycle other than RNA replication and transcription.
Journal ArticleDOI

Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection

TL;DR: An unbiased cell-based screening system involving multiple rounds of infection in a 96-well format is developed, identifying 33 compounds that targeted both known and previously unexplored aspects of HCV infection, including entry, replication, and assembly.
Journal ArticleDOI

Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication.

TL;DR: The results suggest that EGOT is a lncRNA induced after infection that increases viral replication by antagonizing the antiviral response, providing a novel link between HCV infection and development of liver tumors.
Journal ArticleDOI

The Replication Activity of Influenza Virus Polymerase Is Linked to the Capacity of the PA Subunit To Induce Proteolysis

TL;DR: RNA protection assays of the products obtained with viral polymerase, reconstituted in vivo with model RNAs, indicated that mutations at position 157 led to a selective loss of the ability to synthesize cRNA from the viral RNA template but not to transcribe viral RNA.
Journal ArticleDOI

COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.

TL;DR: In this article, the authors developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S) protein, and evaluated their immunogenicity in mice using DNA/MVA or MVA/mVA prime/boost immunization protocols.